drugset / Trial / NCT07361367

A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult Participants

NCT07361367

Phase 1 Completed 11 enrolled AbbVie
Non-randomizedSequentialOpen-labelTreatment

Summary

The objective of this study is to evaluate the PK of a tablet formulation of ABBV-722 under fasted conditions and the effect of food on its bioavailability after administration of single doses

Timeline

Start
2026-01-15
Primary completion
2026-03-23
Completion
2026-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-722 Unknown Oral

Indications

No indication recorded.